{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-22-000049","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.145347+00:00","generated_at":"2026-06-21T15:01:10.560253+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance","bullets":["$40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.","Total potential milestone payments up to $1.2 billion; $100 million earned to date including this payment.","Novo Nordisk acquired full worldwide rights to ATTR amyloidosis pipeline from Prothena in July 2021.","Phase 2 study addresses high unmet need in moderate to advanced ATTR amyloidosis with risk of early mortality."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-22-000049","json":"https://secwatch.observer/filing/0001559053-22-000049.json","markdown":"https://secwatch.observer/filing/0001559053-22-000049.md","text":"https://secwatch.observer/filing/0001559053-22-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/0001559053-22-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905322000049/prta-20221121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:01:10.560253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}